Literature DB >> 7711985

The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients.

H Koyuncuoglu1.   

Abstract

According to the hypothesis implying that the main mechanism underlying opiate addiction is the blockade by opiates of NMDA receptor functions and subsequent upregulation and supersensitivity of the receptors, noncompetitive NMDA receptor blocker dextromethorphan (DM) has been successfully used in the heroin addict treatment. As the stimulation of NMDA receptors modulates the release of neurotransmitters and hormones such as NE, D, ACh, GH, LH, LSH, ACTH etc., all of which have been found responsible for the manifestation of abstinence syndrome signs including craving and neuronal death by excessive stimulation of NMDA receptors, the incomplete blockade of the NMDA receptors minimizes the intensity of the abstinence syndrome and provides the downregulation of the receptors. In the present study, tizanidine (TIZ), which inhibits the release of endogenous excitatory aminoacids by the agonistic activity on alpha 2-adrenoreceptors, was combined with DM to obtain further benefits. Forty-four male and three female heroin addicts were the subjects of the study. Their daily mean heroin intake was about 2.28 g street heroin. The main duration of heroin use was approximately 3.4 years. Two to three hours after abrupt withdrawal, the outpatients were given 15 mg DM every hour, 25 or 50 mg chlorpromazine (CPZ) + 4 mg TIZ every six hours and 10 mg diazepam + 10 mg hyoscine N-butyl Br + 250 mg dipyrone every six hours three hours following CPZ. The addicts were controlled twice a day. Yawning, rhinorrhea, perspiration, piloerection, restlessness, insomnia, emesis, diarrhea, craving, rejection of smoking and pupils were observed and/or questioned. Two of the 47 outpatients took heroin on the first days.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7711985

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  5 in total

Review 1.  Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?

Authors:  Timothy E Albertson; James Chenoweth; Jonathan Ford; Kelly Owen; Mark E Sutter
Journal:  J Med Toxicol       Date:  2014-12

2.  Evaluation of the reinforcing and subjective effects of heroin in combination with dextromethorphan and quinidine.

Authors:  Suzanne K Vosburg; Maria A Sullivan; Sandra D Comer
Journal:  J Opioid Manag       Date:  2011 Nov-Dec

3.  Comparison of the efficacy of buprenorphine and clonidine in detoxification of opioid-dependents.

Authors:  Hassan Ziaaddini; Mansooreh Nasirian; Nouzar Nakhaee
Journal:  Addict Health       Date:  2012 Summer-Autumn

4.  Dextromethorphan and quinidine combination for heroin detoxification.

Authors:  Evaristo Akerele; Adam Bisaga; Maria A Sullivan; Fatima Garawi; Sandra D Comer; Anil A Thomas; Edward V Nunes; Herbert D Kleber
Journal:  Am J Addict       Date:  2008 May-Jun

5.  The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity.

Authors:  Keith A Trujillo
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.